MediciNova Inc

MediciNova announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study, an expanded access program evaluating MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis. The study is funded by the National Institute of Neurological Disorders and Stroke under the ACT for ALS initiative and provides the investigational drug to individuals with ALS who are not eligible for ongoing randomized clinical trials. Final patient follow-ups are projected to conclude in early 2027, after which data analysis will begin to support scientific presentations and peer-reviewed publications. MN-166 is an orally available small-molecule inhibitor of phosphodiesterase-4 and inflammatory cytokines, and MediciNova previously completed enrollment in its COMBAT-ALS Phase 2b/3 clinical trial of the same compound in September 2025.

MediciNova has completed the last patient last visit in its Phase 2 clinical trial of MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes, with top-line data expected in the third quarter of 2026. The company also enrolled 100 patients, half of the planned 200, in the SEANOBI expanded-access program evaluating MN-166 (ibudilast) in amyotrophic lateral sclerosis. A U.S. patent notice of allowance was received for ibudilast combined with an anti-PD-1 antibody for glioblastoma, expiring no earlier than September 2042. Additionally, a peer-reviewed study showed ibudilast can block brain metastasis growth by inhibiting MIF-CD74 signaling. MediciNova now has four equity research firms covering the stock, up from one eighteen months ago, and expects topline data from its COMBAT ALS Phase 2b/3 registration trial by the end of 2026.